California State Teachers Retirement System raised its stake in Retrophin Inc. (NASDAQ:RTRX) by 2.5% during the second quarter, Holdings Channel reports. The fund owned 75,938 shares of the biopharmaceutical company’s stock after buying an additional 1,869 shares during the period. California State Teachers Retirement System owned 0.21% of Retrophin worth $1,352,000 as of its most recent filing with the SEC.

Other large investors have also modified their holdings of the company. GW&K Investment Management LLC increased its stake in shares of Retrophin by 12.2% in the second quarter. GW&K Investment Management LLC now owns 95,987 shares of the biopharmaceutical company’s stock valued at $1,710,000 after buying an additional 10,465 shares during the last quarter. Boston Advisors LLC increased its position in Retrophin by 23.8% in the second quarter. Boston Advisors LLC now owns 26,945 shares of the biopharmaceutical company’s stock valued at $480,000 after buying an additional 5,185 shares during the last quarter. Bank of Montreal Can purchased a new position in Retrophin during the second quarter valued at approximately $368,000. Scopia Capital Management LP increased its position in Retrophin by 874.8% in the first quarter. Scopia Capital Management LP now owns 3,598,222 shares of the biopharmaceutical company’s stock valued at $49,152,000 after buying an additional 3,229,087 shares during the last quarter. Finally, Renaissance Technologies LLC purchased a new position in Retrophin during the first quarter valued at approximately $1,046,000.

Shares of Retrophin Inc. (NASDAQ:RTRX) traded down 2.02% during mid-day trading on Thursday, reaching $23.27. The company’s stock had a trading volume of 650,556 shares. Retrophin Inc. has a one year low of $11.60 and a one year high of $24.57. The stock has a market cap of $854.73 million, a P/E ratio of 9.45 and a beta of 1.11. The stock has a 50 day moving average of $18.93 and a 200-day moving average of $16.90.

Retrophin (NASDAQ:RTRX) last released its quarterly earnings data on Thursday, August 4th. The biopharmaceutical company reported $0.07 EPS for the quarter, beating analysts’ consensus estimates of ($0.23) by $0.30. Retrophin had a negative return on equity of 0.52% and a net margin of 83.57%. The firm had revenue of $33.30 million for the quarter, compared to analysts’ expectations of $32.73 million. Retrophin’s quarterly revenue was up 38.2% compared to the same quarter last year. On average, equities research analysts expect that Retrophin Inc. will post $0.09 EPS for the current fiscal year.

Several research analysts have commented on RTRX shares. Leerink Swann restated a “buy” rating and set a $4.00 price objective on shares of Retrophin in a report on Tuesday, June 21st. BMO Capital Markets reaffirmed a “buy” rating on shares of Retrophin in a research report on Monday, June 20th. Zacks Investment Research cut Retrophin from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, July 6th. Finally, JMP Securities reaffirmed a “buy” rating on shares of Retrophin in a research report on Saturday, July 9th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. Retrophin has an average rating of “Buy” and an average price target of $27.60.

In related news, EVP Alvin Shih sold 8,750 shares of the company’s stock in a transaction that occurred on Thursday, September 1st. The stock was sold at an average price of $16.24, for a total value of $142,100.00. Following the transaction, the executive vice president now directly owns 158,334 shares in the company, valued at $2,571,344.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 2.41% of the stock is owned by corporate insiders.

About Retrophin

Retrophin, Inc is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age.

5 Day Chart for NASDAQ:RTRX

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc. (NASDAQ:RTRX).

Receive News & Ratings for Retrophin Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin Inc. and related companies with MarketBeat.com's FREE daily email newsletter.